NVO - Novo Nordisk A/S logo

NVO

Novo Nordisk A/S

9.5/10top 1%Net income grew 100% of years20Y
Compare NVO Hold

Novo Nordisk A/S develops, manufactures, and distributes pharmaceutical products, focusing on diabetes, obesity, and rare diseases. Its offerings include insulin pens, hormone therapies, and treatment solutions for rare blood and endocrine disorders across multiple regions.

⚕️ Healthcare NYSE Listed 1982 kr DKK
$1,000 invested 30 years ago →$96,427today

Score Overview

1 Year
Score
Net Growth13.68%
Net TrendGrew
Net Income Consistency—
Rev Growth6.59%
Rev TrendGrew
Revenue Consistency—
5 Years
Score9.4
Net Growth143.82%
Net TrendEvery year
Net Income Consistency—
Rev Growth133.97%
Rev TrendEvery year
Revenue Consistency—
10 Years
Score
Net Growth207.03%
Net TrendEvery year
Net Income Consistency
Rev Growth194.71%
Rev Trend90%
Revenue Consistency
20 Years
Score9.5
Net Growth18x
Net TrendEvery year
Net Income Consistency
Rev Growth8x
Rev Trend95%
Revenue Consistency
30 Years
Score
Net Growth64x
Net TrendEvery year
Net Income Consistency
Rev Growth22x
Rev Trend93%
Revenue Consistency
All Time
Score
Net Growth191x
Net Trend95%
Net Income Consistency
Rev Growth79x
Rev Trend95%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Novo Nordisk A/S has ranked, year by year

Measure
Fundamentals Window
1Y5Y10Y20Y

Showing 20 years ranking history by HDB Score.

Top 50 on HDB Score for 16 consecutive years, since 2006, through 2021.

  • NVO

2006: 5.1% · 2021: 0.1% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-14
$ 43.45—
1 Year2025-09-12
$ 52.26-16.86%
5 Years2021-09-14
$ 44.60-2.58%
10 Years2016-09-14
$ 18.23138.36%
20 Years2006-09-14
$ 2.4717x
30 Years1996-09-13
$ 0.4596x
All Time1982-01-04
$ 0.10424x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026kr 329.43Bkr 116.44B
2025kr 309.06Bkr 102.43Bkr 26.96B
2024kr 290.40Bkr 100.98Bkr 26.30B
2023kr 232.26Bkr 83.68Bkr 30.23B
2022kr 176.95Bkr 55.52Bkr 23.57B
2021kr 140.80Bkr 47.75Bkr 17.48B
2020kr 126.94Bkr 42.13Bkr 2.09B
2019kr 122.02Bkr 38.95Bkr 2.32B
2018kr 111.83Bkr 38.62Bkr 15.63B
2017kr 111.69Bkr 38.13Bkr 18.85B
2016kr 111.78Bkr 37.92Bkr 20.69B
2015kr 107.92Bkr 34.86Bkr 20.46B
2014kr 88.80Bkr 26.48Bkr 15.90B
2013kr 83.57Bkr 25.18Bkr 14.46B
2012kr 78.02Bkr 21.43Bkr 16.10B
2011kr 66.34Bkr 17.09Bkr 17.50B
2010kr 60.77Bkr 14.40Bkr 16.05B
2009kr 51.07Bkr 10.76Bkr 12.82B
2008kr 45.66Bkr 9.66Bkr 10.18B
2007kr 41.88Bkr 8.53Bkr 7.38B
2006kr 38.75Bkr 6.45Bkr 5.10B
2005kr 33.71Bkr 5.85Bkr 5.01B
2004kr 29.23Bkr 5.04Bkr 3.98B
2003kr 26.61Bkr 4.87Bkr 3.09B
2002kr 25.15Bkr 4.09Bkr 1.74B
2001kr 23.71Bkr 3.85Bkr 3.04B
2000kr 20.81Bkr 3.08Bkr 1.27B
1999kr 16.44Bkr 2.41Bkr 1.97B
1998kr 13.64Bkr 2.41Bkr 798M
1997kr 16.98Bkr 2.21Bkr 1.12B
1996kr 14.90Bkr 1.80Bkr 1.57B
1995kr 13.71Bkr 1.56Bkr 2.99B
1994kr 13.51Bkr 1.43Bkr 6.68B
1993kr 13.14Bkr 1.43Bkr 5.70B
1992kr 10.67Bkr 1.27Bkr 5.81B
1991kr 9.82Bkr 930Mkr 6.03B
1990kr 8.33Bkr 760Mkr 4.33B
1989kr 7.61Bkr 745Mkr 2.94B
1988kr 5.62Bkr 637Mkr 2.52B
1987kr 5.02Bkr 480Mkr 2.04B
1986kr 4.18Bkr 521Mkr 1.99B
1985kr 4.15Bkr 607Mkr 2.10B
NVO - Novo Nordisk A/S logo

Novo Nordisk A/S fundamental performance

Between 2005 and 2025, revenue grew from kr 33.71B to kr 309.06B and net income grew from kr 5.85B to kr 102.43B. Revenue increased in 19 of those 20 years; net income in every one.

Across Novo Nordisk A/S's full reported history, from 1985 to 2025, revenue grew from kr 4.15B to kr 309.06B and net income grew from kr 607M to kr 102.43B. Revenue increased in 95% of the years measured; net income in 95%.

Novo Nordisk A/S currently holds a 20-year HDB Score of 9.5 out of 10. How the HDB Score is calculated.

Membership

Continue NVO’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,827 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies